Page 39 - Eppendorf News Today

Pi-Cardia announced today that it completed a successful first-in-human treatment of the mitral valve with its ShortCut device.

DGAP-News: Pi-Cardia Ltd. / Key word(s): Miscellaneous Pi-Cardia Successfully Performs Mitral Valve Splitting With ShortCut™ 22.08.2022 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Pi-Cardia Successfully Performs Mitral Valve Splitting with ShortCut™ Fi...

Many of the microbes that live in our gut are good for our health, while others contribute to inflammatory bowel disease or other disorders.

Researchers suggest specialized viruses can selectively kill harmful gut bacteria that cause inflammatory bowel disease and other disorders.

A promising 'phage cocktail' may become the basis for future therapies for other disorders affected by gut microbes, including obesity, diabetes and perhaps even cancer.

New Eppendorf subsidiary features a high-tech laboratory for pipette calibration and offers an extensive range of high-quality laboratory services The Eppendorf Group continues its growth track in Asia in a targeted manner and has opened a new site in Singapore. Click to read more...

Laser additive manufacturing enabling more durable, better-fitting false teeth.

The globally active Eppendorf Group continues its growth track in Asia in a targeted manner and has opened a new site in Singapore. The new subsidiary is located in the heart of Singapore’s modern ...

This rare phenomenon can occur in Covid-19 patients after treatment with the antiviral drug Paxlovid.

Remdesivir is alleged to play a controversial role in Covid deaths.